FR104 / Asahi Kasei, OSE Immunotherapeutics  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FR104 / OSE Immunotherapeutics, Asahi Kasei
NCT02800811: Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

Completed
1
64
Europe
FR104, Placebo
OSE Immunotherapeutics
Rheumatoid Arthritis, Complication of Transplant
06/16
07/16
NCT05238493: A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Completed
1
60
US
VEL-101, Placebo
Veloxis Pharmaceuticals
Healthy Volunteers
01/23
01/23

Download Options